Skip to main content
NASDAQ:PBLA

Panbela Therapeutics Stock Forecast, Price & News

$3.83
+0.01 (+0.26 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.83
$4.02
50-Day Range
$3.82
$4.70
52-Week Range
$2.37
$10.00
Volume20,297 shs
Average Volume129,290 shs
Market Capitalization$38.64 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PBLA News and Ratings via Email

Sign-up to receive the latest news and ratings for Panbela Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Panbela Therapeutics logo

About Panbela Therapeutics

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was founded in 2011 and is based in Waconia, Minnesota.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PBLA
CUSIPN/A
CIKN/A
Phone952 479 1196
Employees5
Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap$38.64 million
Next Earnings Date8/11/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

263rd out of 2,044 stocks

Pharmaceutical Preparations Industry

111th out of 769 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Panbela Therapeutics (NASDAQ:PBLA) Frequently Asked Questions

Is Panbela Therapeutics a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Panbela Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Panbela Therapeutics stock.
View analyst ratings for Panbela Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Panbela Therapeutics?

Wall Street analysts have given Panbela Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Panbela Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Panbela Therapeutics' next earnings date?

Panbela Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Panbela Therapeutics
.

How were Panbela Therapeutics' earnings last quarter?

Panbela Therapeutics, Inc. (NASDAQ:PBLA) issued its quarterly earnings results on Wednesday, May, 12th. The company reported ($0.23) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.12.
View Panbela Therapeutics' earnings history
.

What price target have analysts set for PBLA?

1 brokers have issued 12-month price targets for Panbela Therapeutics' stock. Their forecasts range from $8.00 to $8.00. On average, they expect Panbela Therapeutics' stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 108.9% from the stock's current price.
View analysts' price targets for Panbela Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Panbela Therapeutics' key executives?

Panbela Therapeutics' management team includes the following people:
  • Dr. Michael T. Cullen Jr., Co-Founder & Exec. Chairman (Age 75, Pay $457.75k)
  • Dr. Jennifer K. Simpson CRNP, Ph.D., M.S.N., C.R.N.P., CEO, Pres & Director (Age 53, Pay $369.92k)
  • Ms. Susan Horvath, VP of Fin., CFO, Sec. & Treasurer (Age 62, Pay $316k)
  • Dr. Thomas X. Neenan, Co-Founder & Chief Scientific Officer
  • Ms. Tammy Groene, VP of Operations
  • Dr. Suzanne Gagnon, Chief Medical Officer & Director (Age 64)

Who are some of Panbela Therapeutics' key competitors?

What is Panbela Therapeutics' stock symbol?

Panbela Therapeutics trades on the NASDAQ under the ticker symbol "PBLA."

Who are Panbela Therapeutics' major shareholders?

Panbela Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Fieldpoint Private Securities LLC (1.82%).

Which institutional investors are buying Panbela Therapeutics stock?

PBLA stock was bought by a variety of institutional investors in the last quarter, including Fieldpoint Private Securities LLC.

How do I buy shares of Panbela Therapeutics?

Shares of PBLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Panbela Therapeutics' stock price today?

One share of PBLA stock can currently be purchased for approximately $3.83.

How much money does Panbela Therapeutics make?

Panbela Therapeutics has a market capitalization of $38.64 million.

How many employees does Panbela Therapeutics have?

Panbela Therapeutics employs 5 workers across the globe.

What is Panbela Therapeutics' official website?

The official website for Panbela Therapeutics is www.panbela.com.

How can I contact Panbela Therapeutics?

The company can be reached via phone at 952 479 1196.


This page was last updated on 5/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.